Medical Research Finder

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

Gut microbiota / Evidence-based microbiome knowledge (incl. AI chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Cardiovascular disease (CVD) & Trimethylamine-N-oxide (TMAO)

Welcome to meRfi-GM!

Please register to continue your trial period!

meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Trimethylamine-N-oxide (TMAO) has been associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD) and related complications. It is considered both an independent risk factor and a prognostic index for patients with cardiovascular disease
Zheng & He 2022 Curr Vasc Pharmacol. 20(1): 29-36
Canyelles et al. 2023 Int J Mol Sci. 24(3): 1940

Trimethylamine-N-oxide (TMAO) may be beneficial as a prognostic marker , representing the degree of gut microbiota dysbiosis and, subsequently, Cardiovascular Disease (CVD) events
Kirichenko et al. 2020 Front. Cell Dev. Biol. 8: 586189
Curini & Amedei 2021 Biomedicines 9: 1338
Hoseini‑Tavassol & Hasani‑Ranjbar 2021 J Diabetes Metab Disord 20(1): 1095-1097

High levels of Trimethylamine-N-oxide (TMAO) are thought to contribute to [atherosclerosis](br…

References (Sources)

A Novel Insight at Atherogenesis: The Role of Microbiome
Kirichenko et al. 2020 Front. Cell Dev. Biol. 8: 586189
Review
Cardiovascular Diseases and Pharmacomicrobiomics: A Perspective on Possible Treatment Relevance
Curini & Amedei 2021 Biomedicines 9: 1338
Review
Impact of trimethylamine N-oxide (TMAO) metaorganismal pathway on cardiovascular disease
Zhao & Wang 2020 J Lab Precis Med. doi:10.21037/jlpm.2020.01.01.
Microbiota and metabolites in metabolic diseases
Cani 2019 Nat. Rev. Endocrinol. 15: 69-70
Review
Plasma trimethylamine N-Oxide and risk of cardiovascular events in patients with type 2 diabetes
Croyal et al. 2020 The Journal of Clinical Endocrinology & Metabolism 105(7): 2371-2380
The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases
Zhen et al. 2023 Front. Endocrinol. 14: 1085041
Review
Trimethylamine N-oxide in atherogenesis: impairing endothelial self-repair capacity and enhancing monocyte adhesion
Ma et al. 2017a Bioscience Reports 37: BSR20160244

AI Chat

5/29/2026

Chat with our artificial intelligence: